Recombinant Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)
![Western blot - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)](https://www.abcam.com/ps/products/125/ab125001/Images/ab125001-414660-anti-retinoid-x-receptor-alpharxra-antibody-epr7106-western-blot-hct116-wt-rxra-knockout-hct116-hela-mcf7.jpg "Western blot - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR7106] to Retinoid X Receptor alpha/RXRA
- Suitable for: WB, IP, ICC/IF
- Knockout validated
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106]
See all Retinoid X Receptor alpha/RXRA primary antibodies -
Description
Rabbit monoclonal [EPR7106] to Retinoid X Receptor alpha/RXRA -
Host species
Rabbit -
Tested applications
Suitable for: WB, IP, ICC/IFmore details
Unsuitable for: Flow Cyt or IHC-P -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide corresponding to Human Retinoid X Receptor alpha/RXRA (N terminal).
-
Positive control
- WB: HCT116, MCF7, HeLa, K562, RAW 264.7, PC12 and NIH 3T3 cell lysates. ICC: MCF7 cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Dissociation constant (KD)
KD = 1.40 x 10 -12 M Learn more about KD -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 0.05% BSA, 40% Glycerol -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR7106 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab125001 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | (3) |
1/1000 - 1/10000. Detects a band of approximately 54 kDa (predicted molecular weight: 51 kDa).
|
| IP |
1/10 - 1/100.
|
|
| ICC/IF |
1/500.
For unpurified use at 1/100 - 1/250. |
| Notes |
|---|
|
WB
1/1000 - 1/10000. Detects a band of approximately 54 kDa (predicted molecular weight: 51 kDa). |
|
IP
1/10 - 1/100. |
|
ICC/IF
1/500. For unpurified use at 1/100 - 1/250. |
Target
-
Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes. -
Tissue specificity
Highly expressed in liver, also found in lung, kidney and heart. -
Sequence similarities
Belongs to the nuclear hormone receptor family. NR2 subfamily.
Contains 1 nuclear receptor DNA-binding domain. -
Domain
Composed of three domains: a modulating N-terminal domain (AF1 domain), a DNA-binding domain and a C-terminal ligand-binding domain (AF2 domain). -
Post-translational
modificationsPhosphorylated on serine and threonine residues mainly in the N-terminal modulating domain. Constiutively phosphorylated on Ser-21 in the presence or absence of ligand. Under stress conditions, hyperphosphorylated by activated JNK on Ser-56, Ser-70, Thr-82 and Ser-260 (By similarity). Phosphorylated on Ser-27, in vitro, by PKA. This phosphorylation is required for repression of cAMP-mediated transcriptional activity of RARA.
Sumoylation negatively regulates transcriptional activity. Desumoylated specifically by SENP6. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 6256 Human
- Entrez Gene: 20181 Mouse
- Entrez Gene: 25271 Rat
- Omim: 180245 Human
- SwissProt: P19793 Human
- SwissProt: P28700 Mouse
- SwissProt: Q05343 Rat
- Unigene: 590886 Human
see all -
Alternative names
- FLJ00280 antibody
- FLJ00318 antibody
- FLJ16020 antibody
see all
Images
-
Western blot - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)All lanes : Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001) at 1/1000 dilution
Lane 1 : Wild-type HCT116 cell lysate
Lane 2 : RXRA knockout HCT116 cell lysate
Lane 3 : HeLa cell lysate
Lane 4 : MCF7 cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 51 kDa
Observed band size: 53 kDa why is the actual band size different from the predicted?Lanes 1 - 4: Merged signal (red and green). Green - ab125001 observed at 53 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
ab125001 was shown to react with Anti-Retinoid X Receptor alpha in HCT 116 wild-type cells in western blot with loss of signal observed in RXRA knockout cell line ab273708 (RXRA knockout cell lysate ab275245). HCT 116 wild-type and RXRA knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab125001 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
![Western blot - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)](https://www.abcam.com/ps/products/125/ab125001/Images/ab125001-299025-anti-retinoid-x-receptor-alpha-antibody-epr7106-western-blot.jpg)
Western blot - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)All lanes : Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001) at 1/1000 dilution (purified)
Lane 1 : PC-12 (Rat adrenal gland pheochromocytoma) whole cell lysates
Lane 2 : NIH/3T3 (Mouse embryonic fibroblast) whole cell lysates
Lane 3 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysates
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 51 kDaBlocking and diluting buffer: 5% NFDM/TBST.
-
![Immunoprecipitation - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)](https://www.abcam.com/ps/products/125/ab125001/Images/ab125001-298869-anti-retinoid-x-receptor-alpha-antibody-epr7106-immunoprecipitation.jpg)
Immunoprecipitation - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)ab125001 (purified) at 1:20 dilution (0.6μg) immunoprecipitating Retinoid X Receptor alpha/RXRA in HeLa whole cell lysate.
Lane 1: HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate, 10μg.
Lane 2 (+): ab125001 & HeLa whole cell lysate
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab125001 in HeLa whole cell lysate
For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1:1000 dilution.
Blocking and diluting buffer: 5% NFDM/TBST. -
![Immunocytochemistry/ Immunofluorescence - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)](https://www.abcam.com/ps/products/125/ab125001/Images/ab125001-298501-anti-retinoid-x-receptor-alpha-antibody-epr7106-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)Immunocytochemistry analysis of MCF7 (Human breast adenocarcinoma epithelial cell) cells labeling Retinoid X Receptor alpha/RXRA with Purified ab125001 at 1:500 dilution. Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor ® 594) 1:200 (2.5 μg/ml). ab150077 Goat anti rabbit IgG(Alexa Fluor ® 488) was used as the secondary antibody at 1:1000 dilution. DAPI nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.
-
![Western blot - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)](https://www.abcam.com/ps/products/125/ab125001/Images/ab125001-139099-anti-retinoid-x-receptor-alpha-antibody-epr7106-western-blot.jpg)
Western blot - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)All lanes : Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001) at 1/1000 dilution (unpurified)
Lane 1 : MCF7 cell lysate
Lane 2 : HeLa cell lysate
Lane 3 : K562 cell lysate
Lane 4 : RAW 264.7 cell lysate
Lane 5 : PC12 cell lysate
Lane 6 : NIH 3T3 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat anti-Rabbit HRP at 1/2000 dilution
Predicted band size: 51 kDa -
![OI-RD Scanning - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)](https://www.abcam.com/ps/products/125/ab125001/Images/ab125001-139098-anti-retinoid-x-receptor-alpha-antibody-epr7106.jpg)
OI-RD Scanning - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001) -
![Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)](https://www.abcam.com/ps/products/125/ab125001/Images/ab125001-7-benefits-of-recombinant-antibodies.png)
Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (ab125001)
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (14)
ab125001 has been referenced in 14 publications.
- Pei J et al. Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations. Clin Epigenetics 13:61 (2021). PubMed: 33757590
- Song Y et al. A Non-coding HES1 Variant Predisposes Children to Congenital Heart Disease in Chinese Population. Front Cell Dev Biol 9:631942 (2021). PubMed: 33585489
- Cao H et al. Retinoid X Receptor a Regulates DHA-Dependent Spinogenesis and Functional Synapse Formation In Vivo. Cell Rep 31:107649 (2020). PubMed: 32433958
- Zhang S et al. Electro-Acupuncture Promotes the Differentiation of Endogenous Neural Stem Cells via Exosomal microRNA 146b After Ischemic Stroke. Front Cell Neurosci 14:223 (2020). PubMed: 32792909
- Liu J et al. Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A-mediated drug hepatotoxicity. Br J Pharmacol 177:1538-1555 (2020). PubMed: 31670839